---
search:
  boost: 2 
---

# Hypoglycemia Treatments

This is a subcategory of Endocrine Agents.

## Formulary

### Preferred

| Preferred                                        | Generic Name                                                          | Quantity | Time (Days) |
| :----------------------------------------------- | :-------------------------------------------------------------------- | :------: | :---------: |
| Baqsimi One Pack <sup>QL</sup>                   | Clucagon Nasal Powder (all strengths)                                 |    6     |     102     |
| Baqsimi Two Pack <sup>QL</sup>                   | Clucagon Nasal Powder (all strengths)                                 |    3     |     102     |
| Glucagen Hypokit <sup>QL</sup>                   | Glucagon HCI (rDNA) for Inj 1 MG (all strengths)                      |    2     |     34      |
| Glucagon Emerg Kit [Labeler 00002] <sup>QL</sup> |                                                                       |          |             |
| Gvoke <sup>QL</sup>                              | Glucagon Subcutaneous Soln Inj (all strengths & formulations)         |    2     |     34      |
| Zegalogue <sup>QL</sup>                          | Dasiglucagon HCI Soln Subcutaneous Inj (all strengths & formulations) |    2     |     34      |

### Non-Preferred

| Non-Preferred                                            | Generic Name | Quantity | Time (Days) |
| :------------------------------------------------------- | :----------- | :------: | :---------: |
| Glucagon Emerg Kit [Labeler 00548 & 63323] <sup>QL</sup> |              |          |             |

## Length of Authorizations

365 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **two preferred** drugs **OR** the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**QL** - All glucagon products: 2 doses per 34 days 

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=52)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=20)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
